|
Synonyms: STK-001 | STK001
Compound class:
Nucleic acid
Comment: Zorevunersen (STK-001) is an antisense oligonucleotide (ASO) that targets sodium voltage-gated channel alpha subunit 1 (SCN1A) pre-mRNA transcript, to promote an increase in Nav1.1 channel protein in neurons. It is intended as a disease-modifying treatment for Dravet syndrome, where SCN1A haploinsufficiency disrupts Nav1.1 protein production.
Full sequence is: all-P-ambo-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methylcytidine |
| No information available. |
Summary of Clinical Use ![]() |
| Zorevunersen (STK-001) was progressed as a clinical candidate to evaluate its potential as a disease-modifying treatment for SCN1A-related Dravet syndrome [1-2]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04740476 | An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome | Phase 2 Interventional | Stoke Therapeutics, Inc | The SWALLOWTAIL study | |
| NCT04442295 | An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome | Phase 1/Phase 2 Interventional | Stoke Therapeutics, Inc | The MONARCH study | |
| NCT06872125 | A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome | Phase 3 Interventional | Stoke Therapeutics, Inc | ||